INHALED NO FOR THE PREVENTION AND TX OF CHRONIC LUNG DISEASE IN PRETERM INFNT

吸入 NO 用于预防和治疗早产儿慢性肺病

• 批准号: 7607248
• 负责人: CAMILIA R MARTIN
• 金额: $ 0.87万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607248
• 关键词: Adrenal Cortex Hormones; Airway Resistance; Breathing; Bronchodilator Agents; Chronic lung disease; Computer Retrieval of Information on Scientific Projects Database; Diuretics; Funding; Grant; Infant; Institution; Lung diseases; Neonatal; Prematurity of fetus; Prevalence; Prevention; Prevention approach; Pulmonary Hypertension; Research; Research Personnel; Resources; Source; Steroids; Therapeutic; United States; United States National Institutes of Health; Vitamin A; clinically significant; postnatal; surfactant

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic lung disease (CLD) of prematurity has emerged as the most common, lethal and expensive remaining neonatal pulmonary disorder in the United States. The estimated prevalence is 10,000-15,000 cases in the nation. Current therapeutic approaches to prevention and treatment of lung disease of infants, which include antenatal corticosteroid treatment, surfactant replacement, and postnatal administration of steroids, Vitamin A, diuretics and bronchodilators, have not resulted in clinically significant decreases in CLD. Infants with the most severe forms of CLD develop increased airway resistance and findings consistent with pulmonary hypertension with corpulmonale.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 早产儿慢性肺病（CLD）已成为美国最常见、最致命、最昂贵的新生儿肺部疾病。 估计全国流行率为10，000 - 15，000例。 目前预防和治疗婴儿肺部疾病的治疗方法，包括产前皮质类固醇治疗、表面活性剂替代和出生后给予类固醇、维生素A、利尿剂和支气管扩张剂，尚未导致CLD的临床显著降低。 患有最严重形式的CLD的婴儿出现气道阻力增加，并且结果与肺源性心脏病的肺动脉高压一致。